title: [Preoperative chemoradiation therapy for lower rectal cancer].
abstract: To identify appropriate candidates with rectal cancer for preoperative chemoradiation therapy, the local recurrence rate and clinicopathological characteristics of 232 patients with rectal cancer undergoing curative resection in our department were investigated. The local recurrence rates were 3.8%, 10.8% and 16.5% in the Rs, Ra and Rb lesions, respectively. Regarding lower (Rb) rectal cancer, depth of lesion (> a1) and nodal metastasis consisted of high factors for local recurrence. Basing on these results, entry criteria for preoperative chemoradiation therapy were established, and concurrent chemoradiation therapy with fluorouracil and cisplatin was delivered preoperatively in 9 primary cases of locally advanced rectal cancer and 3 cases with local recurrence. A partial response was obtained in 7 of 12 cases with a response rate of 58%, size-reduction of the distant metastatic lesions was found in 2 cases, and clinical symptoms were improved in all cases. The histological responses of the 6 resected cases were Grade 2 in 2 cases and Grade 1b in 4 cases. The toxicities of this chemoradiation regimen were well tolerable. As a postoperative complication, infection of the perineal wound was most frequent. Preoperative chemoradiation therapy with the present regimen would be a useful adjuvant treatment for advanced lower rectal cancer.
authors.affiliation: Dept. of Surgery, Toyonaka Municipal Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Murotani
authors.forename: T
authors.initials: T
authors.lastname: Tsujinaka
authors.forename: M
authors.initials: M
authors.lastname: Takami
authors.forename: T
authors.initials: T
authors.lastname: Takada
authors.forename: M
authors.initials: M
authors.lastname: Kitada
authors.forename: Y
authors.initials: Y
authors.lastname: Tsukahara
authors.forename: T
authors.initials: T
authors.lastname: Shibata
authors.forename: T
authors.initials: T
authors.lastname: Niinobu
authors.forename: K
authors.initials: K
authors.lastname: Iihara
authors.forename: F
authors.initials: F
authors.lastname: Tsukamoto
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Kimura
authors.forename: T
authors.initials: T
authors.lastname: Nose
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D002945:Cisplatin; D005472:Fluorouracil